Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
L Zhang, K Dermawan, M Jin, R Liu, H Zheng, L Xu… - Clinical …, 2008 - Elsevier
Characterized as a mitotic inhibitor, paclitaxel has gained importance as a promising agent
for the treatment of advanced non-small cell lung cancer (NSCLC). However, whether
paclitaxel has immune modulatory effects remains unclear. In this study, we analyzed 55
peripheral blood samples from NSCLC patients who underwent paclitaxel-based
chemotherapy. We found that among the lymphocyte subsets, paclitaxel selectively
decreased the size of the regulatory T cell (Treg) population rather than other subsets …
for the treatment of advanced non-small cell lung cancer (NSCLC). However, whether
paclitaxel has immune modulatory effects remains unclear. In this study, we analyzed 55
peripheral blood samples from NSCLC patients who underwent paclitaxel-based
chemotherapy. We found that among the lymphocyte subsets, paclitaxel selectively
decreased the size of the regulatory T cell (Treg) population rather than other subsets …